Please login to the form below

Not currently logged in
Email:
Password:

Actavis Germany H1 2007 sales increase 21 per cent

Actavis Group, the Icelandic-headquartered generic pharmaceuticals company, has revealed that Germany has become its second-largest market, with EUR 35m in product sales in H1 FY07.

Actavis Group, the Icelandic-headquartered generic pharmaceuticals company, has revealed that Germany has become its second-largest market, with EUR 35m in product sales in H1 FY07.

With Actavis' third party division sales included in the results, total sales in Germany were EUR 66m in H1 FY07. Actavis' largest market is North America, which brought in sales of over EUR 500m in annual sales.

IMS data has also revealed that Actavis Deutschland is the seventh largest generic pharmaceuticals company in Germany, which is also Europe's largest generics market.

Even though market reforms and generic price erosion have reduced the attractiveness of the German market, Actavis has still increased its revenue growth in the region by 21 per cent, compared with H1 FY06 figures. The success has been attributed to Actavis' full product pipeline and sales force of 130 reps, which is set to increase.

The recent preferred partnership contract agreement with Allgemeine Ortskrankenkassen (AOK), Germany's largest General local health insurance provider, has helped ramp up sales. Actavis also provides over 40 products for the VdAK and the AEV insurance associations.

Actavis' deputy CEO, Sigurdur Oli Olafsson, said: "Going forward, we expect to see good growth in our German business, through an increasing number of new product launches, continued alliances with leading German insurance funds, as well as our important partnership arrangements with German generic companies for product supply."

22nd August 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

Tapping the potential of rare diseases: A journey into uncharted territory
...
The 2019 WHO essential medicine list: Narrowing the access gap to innovative cancer treatments
The essential medicine list (EML) contains treatments considered to be the most effective and safe in targeting global health concerns. On 9 July 2019, the World Health Organization (WHO) published...
NICE
Evolution or revolution: the latest review of NICE methods
By Leela Barham...

Infographics